Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma
NCT ID: NCT02555267
Last Updated: 2023-02-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
148 participants
OBSERVATIONAL
2015-09-30
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Geriatric Assessments in Elderly Diffuse Large B-cell Lymphoma Patients-2 (GERIAD2)
NCT03211702
Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
NCT04113226
Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL
NCT06150053
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
NCT02474550
Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL
NCT03465527
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Elderly patients with DLBCL
Elderly patients (age\>=65 years) with DLBCL treated with R-CHOP chemotherapy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 65 years old or over
* Scheduled to receive R-CHOP chemotherapy
* Informed consent
Exclusion Criteria
* Primary central nervous system DLBCL
* Patients with a diagnosis of cancer (other than basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, well differentiated thyroid cancer \[papillary or follicular thyroid cancer\]) within 3 years before the study entry or with any treatment for cancer within 3 years before entry
* Consent withdrawal
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Catholic University of Korea
OTHER
Kyungpook National University Hospital
OTHER
Keimyung University Dongsan Medical Center
OTHER
Korea University Anam Hospital
OTHER
Korea University Guro Hospital
OTHER
Kosin University Gospel Hospital
OTHER
Pusan National University Hospital
OTHER
Soonchunhyang University Hospital
OTHER
Ajou University School of Medicine
OTHER
Chonnam National University Hospital
OTHER
Chonbuk National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ho-Young Yhim
Assistant professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ho-Young Yhim, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Chonbuk National University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chonbuk National University Hospital
Jeonju, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GERIAD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.